Roche: presents test for Alzheimer's disease

(CercleFinance.com) - Roche today announced late-breaking new data on its Elecsys amyloid plasma panel (combination of pTau181 and ApoE4) , for Alzheimer's disease, at the 17th Clinical Trials in Alzheimer's Disease (CTAD) congress in Madrid, Spain.


The results show that the test, currently in development, could accurately exclude amyloid pathology - a hallmark of Alzheimer's disease - in a large population with a variety of cognitive disorders.

"This could enable clinicians to exclude Alzheimer's disease as a possible cause of cognitive symptoms with a simple blood test, offering certainty and assurance" says the group.

In the largest global clinical trial of its kind, the blood test showed very good accuracy in excluding Alzheimer's pathology in people studied for this disease, potentially avoiding the need for other invasive and unnecessary tests.

' ''The data from this large-scale study of people with cognitive impairment suggest that a simple, rapid blood test could reliably exclude amyloid pathology, providing much-needed reassurance to patients and their families,'' commented Matt Sause, CEO of Roche Diagnostics.

' For many people, obtaining a clear and rapid diagnosis remains difficult. This test could help patients receive appropriate care as early as possible. '

Copyright (c) 2024 CercleFinance.com. All rights reserved.